A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin

Update Il y a 4 ans
Reference: EUCTR2006-001219-31

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

1. To demonstrate the effect of vildagliptin on the incretin mediated enhancement of insulin secretion (75 g oral glucose vs. matched i.v. glucose) in patients with T2DM treated with metformin by testing the hypothesis that the improvement of the incretin effect assessed as C-peptide IAUC(0-4hr) with vildagliptin 100 mg qd is superior to that with placebo after 2 weeks of treatment.


Inclusion criteria

  • Type II Diabetes

Links